Alphatec Holdings, Inc. (NASDAQ:ATEC) CEO Sells $80,244.00 in Stock

Alphatec Holdings, Inc. (NASDAQ:ATEC) CEO Patrick Miles sold 6,687 shares of the firm’s stock in a transaction dated Tuesday, January 21st. The stock was sold at an average price of $12.00, for a total transaction of $80,244.00. Following the sale, the chief executive officer now directly owns 5,501,715 shares in the company, valued at $66,020,580. This represents a 0.12 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Alphatec Stock Down 5.7 %

ATEC stock opened at $11.01 on Friday. The company has a quick ratio of 1.15, a current ratio of 2.32 and a debt-to-equity ratio of 30.21. The firm’s 50-day simple moving average is $9.92 and its 200 day simple moving average is $8.08. The stock has a market cap of $1.56 billion, a PE ratio of -8.60 and a beta of 1.41. Alphatec Holdings, Inc. has a fifty-two week low of $4.88 and a fifty-two week high of $17.34.

Institutional Trading of Alphatec

Hedge funds and other institutional investors have recently made changes to their positions in the stock. R Squared Ltd bought a new position in Alphatec during the 4th quarter valued at $29,000. Nisa Investment Advisors LLC boosted its stake in Alphatec by 973.3% during the fourth quarter. Nisa Investment Advisors LLC now owns 4,669 shares of the medical technology company’s stock valued at $43,000 after buying an additional 4,234 shares in the last quarter. XTX Topco Ltd acquired a new position in Alphatec during the third quarter worth about $69,000. Net Worth Advisory Group bought a new stake in Alphatec in the third quarter worth about $76,000. Finally, Van ECK Associates Corp lifted its holdings in Alphatec by 57.0% in the 3rd quarter. Van ECK Associates Corp now owns 19,273 shares of the medical technology company’s stock valued at $99,000 after acquiring an additional 6,998 shares during the last quarter. 66.35% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on ATEC shares. Barclays upped their price objective on shares of Alphatec from $20.00 to $21.00 and gave the company an “overweight” rating in a research note on Wednesday. Needham & Company LLC raised their price objective on Alphatec from $13.00 to $16.00 and gave the stock a “buy” rating in a report on Monday, January 13th. Finally, HC Wainwright reiterated a “buy” rating and issued a $20.00 target price on shares of Alphatec in a research note on Tuesday, January 14th. One investment analyst has rated the stock with a hold rating and eight have assigned a buy rating to the stock. According to MarketBeat.com, Alphatec presently has a consensus rating of “Moderate Buy” and a consensus target price of $17.56.

About Alphatec

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.